GBA1 and hepatocellular carcinoma: On the basis of the difference in phenotypic sensitivity of GBAKO hepatocellular carcinoma and SCC cells to GlcCer synthase inhibition, we speculate that malignancy associated with alterations in sphingolipid metabolism are driven by the activity of GlcCer synthase in hepatocellular carcinoma, and by GBA activity in SCC and ovarian cancer-derived cells.